HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage

M Carrington1, G W Nelson, M P Martin

  • 1Intramural Research Support Program, Science Applications International Corporation Frederick, National Cancer Institute (NCI), Frederick, MD 21702-1201, USA.

Science (New York, N.Y.)
|March 12, 1999
PubMed

Related Concept Videos